Company Profile (AI Text)
Name: OncoSynergy
Canonical URL: https://wefunder.com/oncosynergy
Updated at: 2026-06-02T05:00:04Z

Tagline: Platform drugs for orphan diseases like Cancer and Ebola
Description: What they do: OncoSynergy develops platform drugs to treat orphan diseases. Their lead antibody drug candidate, OS2966, is effective in treating therapy resistant and metastatic cancers in animals. OS2966 also shows an ability to inhibit Ebola in the lab and will soon be tested on primates.Why it's a big deal: They’re taking a completely new approach to drug development. Most drugs interfere with specific molecules that help a disease's cells grow and survive, which ultimately fails because diseases are driven by more than one molecule. The disease just adapts and becomes more aggressive. Just like Aspirin acts as an anti-fever, anti-pain, anti-inflammation, and anti-clotting drug, OS2966 blocks multiple molecules that drive the disease simultaneously. Scientists have been looking for a way to deploy this kind of treatment for decades, and OncoSynergy is one of the first to develop platform drug candidates that have been tested safely in large mammals and primates. OS2966 has enormous potential for improving the standard of care for patients with deadly diseases.

Key claims:
- Total raised on Wefunder: 178475 | citation: https://wefunder.com/oncosynergy#claim-total-raised
- Total investors: 35 | citation: https://wefunder.com/oncosynergy#claim-total-investors

Verified facts:
- Total raised on Wefunder: 178475 | observed_at: 2026-06-02T05:00:04Z | expires_at: 2026-06-03T05:00:04Z
- Total investors: 35 | observed_at: 2026-06-02T05:00:04Z | expires_at: 2026-06-03T05:00:04Z

Computed metrics:
- total_amount_raised: 178475
- total_investors: 35
- team_size: 6
- featured_investor_count: 0
- faq_count: 5
- recent_post_count: 1

Quick facts:
- Platform drug for the treatment of very serious diseases. | citation: https://wefunder.com/oncosynergy#claim-fact-1
- Dramatic efficacy in clinically relevant cancer models. | citation: https://wefunder.com/oncosynergy#claim-fact-2
- Awarded Orphan Drug Designation by the FDA in oncology. | citation: https://wefunder.com/oncosynergy#claim-fact-3
- Only multi-mechanism experimental Ebola drug in development. | citation: https://wefunder.com/oncosynergy#claim-fact-4
- Founder is a MD, PhD, and Oxford Junior Fellow. | citation: https://wefunder.com/oncosynergy#claim-fact-5

FAQ:
- Q: If all goes well, how long to FDA trials typically take?
  A: Hi Ben, The standard FDA approval process is 5-10 years encompassing Phases 1, 2, and 3. However, there are multiple value inflection points/exit opportunities along the way (e.g., after demonstrating safety in Phase 1 and after demonstrating efficacy in Phase 2) so it is not typical to wait that long before investors can see a return. In addition, there are enhanced FDA programs that can speed up the process if the drug addresses an unmet medical need (here's a link: http://www.fda.gov/forpa...
- Q: At what point in the FDA trials do you become really confident OS2966 has a chance?
  A: Great question, Will. The short answer is Phase 1 (safety/dosing) because that is our next major value inflection point. We have outstanding results in multiple clinically-relevant cancer models so we are reasonably confident the efficacy will translate to humans. Also, a major criterion for the FDA to award Orphan Drug Designation is efficacy in animal models and we have 2 such Designations so far (glioblastoma and ovarian cancer). However, with a "platform drug" approach such as ours the bi...
- Q: Why no valuation cap? What's your rationale...?
  A: Hi Ross, Thank you for the question... a common one, I'm sure. As you know the biotech sector is quite a bit different than the tech sector from the perspective of institutional fundraising. With few exceptions you don't typically see the runaway valuations in a pre-clinical company like us because the biggest perceived value inflection point is early clinical trials. That is our next step so you are just in time. For our first priced round next quarter, we are raising a modest, but sufficien...
- Q: What is the term of the convertible note and at what price per share it will be converted.
  A: Thanks for your question, Harish. We are aiming to close a priced round early next quarter so price will be determined at that time. Further details can be found in my replies below. Thanks again! Shawn
- Q: This is very exciting! Kudos on your work thus far. Why is there no valuation cap in the terms proposed for this investment? What would this mean for current investors if and when there is large funding round in the future or series B?
  A: Hi Dilraj, Thank you so much for your kind words. I am humbled by the response to this campaign. Very exciting. I think I've addressed your question below in my reply to Ross Blankenship. If not, please let me know. Thank you again. Shawn

Recent posts:
- One Step Closer to Clinicals, OncoSynergy Raises $3M Series A (2018-10-22T20:03:32Z) https://wefunder.com/feed/96084